Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis

医学 杜皮鲁玛 特应性皮炎 皮肤病科 药品 药理学
作者
Patrick O. Perche,Madison K. Cook,Steven R. Feldman
出处
期刊:Annals of Pharmacotherapy [SAGE Publishing]
卷期号:57 (1): 86-98 被引量:33
标识
DOI:10.1177/10600280221096713
摘要

Objective The objective of this article is to review abrocitinib, an oral Janus kinase (JAK) 1 inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis (AD). Data Sources A literature search of MEDLINE (PubMed) was performed for articles from inception through end-March 2022 using the following search terms: atopic dermatitis, abrocitinib, PF-04965842, methotrexate, cyclosporine, dupilumab, ruxolitinib, and JAK-STAT pathway. Study Selection and Data Extraction English articles relating to pharmacology, pharmacokinetics, efficacy, and safety of abrocitinib, and other conventional systemic medications for AD, were included. Data Synthesis Across phase IIb and phase III clinical trials, abrocitinib was efficacious with an average of 47.5% patients on 200 mg abrocitinib and 32.0% on 100 mg abrocitinib achieving an Investigator’s Global Assessment (IGA) of 0 or 1 at 12 weeks. In comparison with dupilumab 300 mg subcutaneously every other week, patients on abrocitinib 200 mg once daily had improved disease severity and itch response. The majority of adverse events were not severe and self-limited. Relevance to Patient Care and Clinical Practice Prior to Food and Drug Administration (FDA) approval of abrocitinib, prednisone was the only FDA-approved oral medication for AD. Although biologics such as dupilumab have revolutionized care, some patients prefer oral medications. Compared with clinical trials of conventional AD treatments, abrocitinib appears more effective. Conclusions Abrocitinib is an efficacious oral JAK 1 inhibitor recently FDA-approved for patients ≥ 18 years old with moderate-to-severe AD who have not responded to systemic medications or when contraindicated otherwise.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
虚幻的凝梦完成签到,获得积分10
刚刚
研友_VZG7GZ应助呐呐呐采纳,获得10
1秒前
1秒前
julia驳回了Jasper应助
1秒前
余琳完成签到,获得积分10
1秒前
赵哈哈完成签到,获得积分10
1秒前
背后城完成签到,获得积分10
2秒前
优美的跳跳糖完成签到 ,获得积分10
2秒前
波比冰苏打完成签到,获得积分10
3秒前
量子星尘发布了新的文献求助10
3秒前
mudiboyang发布了新的文献求助10
3秒前
3秒前
卡戎529完成签到 ,获得积分10
3秒前
SJT完成签到,获得积分10
4秒前
背后城发布了新的文献求助10
4秒前
一朵小鲜花儿完成签到,获得积分10
4秒前
li完成签到,获得积分10
4秒前
guoxuefan完成签到,获得积分10
4秒前
yili完成签到,获得积分10
4秒前
4秒前
甜蜜鹭洋完成签到 ,获得积分10
5秒前
清欢小适完成签到 ,获得积分10
5秒前
科研通AI5应助兔子先生采纳,获得10
5秒前
6秒前
小火苗发布了新的文献求助10
6秒前
6秒前
善学以致用应助孙了了采纳,获得10
6秒前
6秒前
小宇OvO完成签到,获得积分20
6秒前
XCHI完成签到 ,获得积分10
8秒前
fdhineodobh花开富贵完成签到,获得积分10
8秒前
9秒前
小宇OvO发布了新的文献求助10
9秒前
畅快的眼神完成签到 ,获得积分10
10秒前
体贴冰棍应助崔雨旋采纳,获得10
10秒前
科研通AI5应助大雄采纳,获得10
10秒前
金桔儿发布了新的文献求助10
11秒前
11秒前
斯文败类应助mudiboyang采纳,获得10
11秒前
11秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
Statistical Methods for the Social Sciences, Global Edition, 6th edition 600
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
Walter Gilbert: Selected Works 500
An Annotated Checklist of Dinosaur Species by Continent 500
岡本唐貴自伝的回想画集 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3661640
求助须知:如何正确求助?哪些是违规求助? 3222598
关于积分的说明 9746930
捐赠科研通 2932253
什么是DOI,文献DOI怎么找? 1605569
邀请新用户注册赠送积分活动 757979
科研通“疑难数据库(出版商)”最低求助积分说明 734584